keyword
MENU ▼
Read by QxMD icon Read
search

arsenic trioxide

keyword
https://www.readbyqxmd.com/read/28427227/high-dose-ascorbate-and-arsenic-trioxide-selectively-kill-acute-myeloid-leukemia-and-acute-promyelocytic-leukemia-blasts-in-vitro
#1
Nélida I Noguera, Elvira Pelosi, Daniela F Angelini, Maria Liliana Piredda, Gisella Guerrera, Eleonora Piras, Luca Battistini, Lauretta Massai, Anna Berardi, Gianfranco Catalano, Laura Cicconi, Germana Castelli, Agnese D'Angiò, Luca Pasquini, Grazia Graziani, Giuseppe Fioritoni, Maria Teresa Voso, Domenico Mastrangelo, Ugo Testa, Francesco Lo-Coco
The use of high-dose ascorbate (ASC) for the treatment of human cancer has been attempted several decades ago and has been recently revived by several in vitro and in vivo studies in solid tumors. We tested the cytotoxic effects of ASC, alone or in combination with arsenic trioxide (ATO) in acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). Leukemic cell lines and primary blasts from AML and APL patients were treated with graded concentrations of ASC, alone or in association with standard concentration (1 μM) of ATO...
March 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28425042/arsenic-trioxide-induced-rhabdomyolysis-a-rare-but-severe-side-effect-in-an-apl-patient-a-case-report
#2
Haiyan He, Ran An, Jian Hou, Weijun Fu
Arsenic trioxide (ATO), a component of the traditional Chinese medicine arsenic sublimate, promotes apoptosis and induces leukemic cell differentiation. Combined with all-trans-retinotic acid (ATRA), ATO has become the first-line induction therapy in treating acute promyelocytic leukemia (APL). The most common side effects of ATO include hepatotoxicity, gastrointestinal symptoms, water-sodium retention, and nervous system damage. In this report, we present a rare side effect, rhabdomyolysis, in a 68-year-old female APL patient who was treated with ATO...
April 19, 2017: Frontiers of Medicine
https://www.readbyqxmd.com/read/28413521/efficacy-of-arsenic-trioxide-drug-eluting-stents-in-the-treatment-of-coronary-heart-disease
#3
Shasha Zhang, Yuping Zhang, Shichuan Li, Zhifeng Li
The aim of the current study was to evaluate the safety and clinical efficacy of arsenic trioxide drug-eluting (AVI) stents, manufactured in China, for the treatment of coronary heart disease (CHD). Between January and August 2014, 40 patients with CHD admitted to Yongchuan Hospital with implanted AVI stents alone were selected. A one-year clinical follow-up was completed and one year postoperative coronary angiography was reviewed. Major adverse cardiovascular events (MACE), recurrent angina, stent restenosis and stent thrombosis cases were detected...
April 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28412241/cathepsin-l-silencing-increases-as2o3-toxicity-in-malignantly-transformed-pilocytic-astrocytoma-mpa58-cells-by-activating-caspases-3-7
#4
Monika Primon, Peter C Huszthy, Helena Motaln, Krishna M Talasila, Hrvoje Miletic, Nadia A Atai, Rolf Bjerkvig, Tamara Lah Turnšek
Low-grade, pilocytic astrocytomas are treated by resection, but additional therapy is necessary for those tumors with anaplastic features. Arsenic trioxide (As2O3) is emerging as an effective chemotherapeutic agent for treatment of malignant glioblastoma multiforme, where Cathepsin L silencing enables lower, less harmful As2O3 concentrations to achieve the desired cytotoxic effect. Here, we evaluated the effects of As2O3 combined with stable Cathepsin L shRNA silencing on cell viability/metabolic activity, and apoptosis in primary cultures of recurrent malignantly transformed pilocytic astrocytoma (MPA)...
April 12, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28404891/hmgb1-promotes-differentiation-syndrome-by-inducing-hyperinflammation-via-mek-erk-signaling-in-acute-promyelocytic-leukemia-cells
#5
Lanlan Tang, Wenwen Chai, Fanghua Ye, Yan Yu, Lizhi Cao, Minghua Yang, Min Xie, Liangchun Yang
Differentiation therapy based on all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL) is complicated by the development of differentiation syndrome (DS), which can be fatal. We examined the role of HMGB1 (high-mobility group box 1) in DS using both in vitro and in vivo models. HMGB1 and the pro-inflammatory cytokines IL-1β and TNF-α were gradually released from NB4 and HL-60 cells treated with ATRA and/or ATO. Similarly, higher serum HMGB1 levels positively correlated with the clinical status of DS patients...
February 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28391263/salvianolic-acid-a-protects-h9c2-cells-from-arsenic-trioxide-induced-injury-via-inhibition-of-the-mapk-signaling-pathway
#6
Jing-Yi Zhang, Gui-Bo Sun, Yun Luo, Min Wang, Wei Wang, Yu-Yang Du, Ying-Li Yu, Xiao-Bo Sun
BACKGROUND/AIMS: This study aimed to investigate whether Salvianolic acid A (Sal A) conferred cardiac protection against Arsenic trioxide (ATO)-induced cardiotoxicity in H9c2 cells by inhibiting MAPK pathways activation. METHODS: H9c2 cardiac cells were exposed to 10 µM ATO for 24 h to induce cytotoxicity. The cells were pretreated with Sal A for 4 h before exposure to ATO. Cell viability was determined utilizing the MTT assay. The percentage of apoptosis was measured by a FITC-Annexin V/PI apoptosis kit for flow cytometry...
April 7, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28357672/overview-of-targeted-therapies-for-adult-t-cell-leukemia-lymphoma
#7
Rihab Nasr, Ambroise Marçais, Olivier Hermine, Ali Bazarbachi
Adult T-Cell Leukemia/lymphoma (ATL) is the first human malignancy associated with a chronic infection by a retrovirus, the human T-cell lymphotropic virus type I (HTLV-I). ATL occurs, after a long latency period, only in about 5% of 10-20 millions infected individuals. ATL has a dismal prognosis with a median survival of less than 1 year, mainly due to its resistance to chemotherapy and to a profound immunosuppression. The viral oncoprotein, Tax, plays a major role in ATL oncogenic transformation by interfering with cell proliferation, cell cycle, apoptosis, and DNA repair...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28352191/retinoic-acid-and-arsenic-trioxide-in-the-treatment-of-acute-promyelocytic-leukemia-current-perspectives
#8
REVIEW
Derek McCulloch, Christina Brown, Harry Iland
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) with a unique morphological appearance, associated coagulopathy and canonical balanced translocation of genetic material between chromosomes 15 and 17. APL was first described as a distinct subtype of AML in 1957 by Dr Leif Hillestad who recognized the pattern of an acute leukemia associated with fibrinolysis, hypofibrinogenemia and catastrophic hemorrhage. In the intervening years, the characteristic morphology of APL has been described fully with both classical hypergranular and variant microgranular forms...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28343272/effect-of-atra-and-ato-on-the-expression-of-tissue-factor-in-nb4-acute-promyelocytic-leukemia-cells-and-regulatory-function-of-the-inflammatory-cytokines-tnf-and-il-1%C3%AE
#9
Sylvie Dunoyer-Geindre, Anne-Sophie Rivier-Cordey, Olga Tsopra, Thomas Lecompte, Egbert K O Kruithof
The characteristic hemorrhages of acute promyelocytic leukemia (APL) are caused in part by the high expression of tissue factor (TF) on leukemic cells, which also produce TNF and IL-1β, proinflammatory cytokines known to increase TF in various cell types. Exposure of NB4 cells, an APL cell line, to all-trans retinoic acid (ATRA) or arsenic trioxide (ATO) rapidly and strongly reduced TF mRNA. Both drugs also reduced TNF mRNA, but later, and moreover increased IL-1β mRNA. The effect on procoagulant activity of cells and microparticles, as measured with calibrated automated thrombography, was delayed and only partial at 24 h...
March 25, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28325224/number-of-succussion-strokes-affects-effectiveness-of-ultra-high-diluted-arsenic-on-in%C3%A2-vitro-wheat-germination-and-polycrystalline-structures-obtained-by-droplet-evaporation-method
#10
Lucietta Betti, Grazia Trebbi, Maria Olga Kokornaczyk, Daniele Nani, Maurizio Peruzzi, Giovanni Dinelli, Paolo Bellavite, Maurizio Brizzi
OBJECTIVES: The aim of this study is to investigate whether the number of succussion strokes applied after each dilution step when preparing the homeopathic treatments influences the effectiveness of ultra-high-diluted (UHD) arsenic trioxide at the 45th decimal dilution/dynamization (As2O3 45x). DESIGN: Wheat seeds, previously stressed with ponderal As2O3, were treated with: As2O3 45x, H2O 45x (dynamized control), or pure water (negative control). The succussion was done manually, and various succussion durations (numbers of strokes) were tested for each treatment...
February 2017: Homeopathy: the Journal of the Faculty of Homeopathy
https://www.readbyqxmd.com/read/28322237/characteristics-and-outcome-of-patients-with-therapy-related-acute-promyelocytic-leukemia-front-line-treated-with-or-without-arsenic-trioxide
#11
S Kayser, J Krzykalla, M A Elliott, K Norsworthy, P Gonzales, R K Hills, M R Baer, Z Ráčil, J Mayer, J Novak, P Žák, T Szotkowski, D Grimwade, N H Russell, R B Walter, E H Estey, J Westermann, M Görner, A Benner, A Krämer, B D Smith, A K Burnett, C Thiede, C Röllig, A D Ho, G Ehninger, R F Schlenk, M S Tallman, M J Levis, U Platzbecker
Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA, and 5% for CTX/ATO/ATRA...
March 21, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28299819/arsenic-trioxide-combined-with-transarterial-chemoembolization-for-primary-liver-cancer-a-meta-analysis
#12
Xiu-He Lv, Chun-Hui Wang, Yan Xie
BACKGROUND: The benefit of combination therapy of arsenic trioxide (As2 O3 ) and transarterial chemoembolization (TACE) is debated. This meta-analysis was conducted to determine whether As2 O3 & TACE therapy achieves better therapeutic effects compared with TACE alone for primary liver cancer. METHODS: A systematic search of both English and Chinese databases was conducted for randomised controlled trials (RCTs). The main outcomes were therapeutic responses, survival rates, improvement in quality of life, and adverse events...
March 15, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28280079/targeted-therapy-for-a-subset-of-acute-myeloid-leukemias-that-lack-expression-of-aldehyde-dehydrogenase-1a1
#13
Maura Gasparetto, Shanshan Pei, Mohammad Minhajuddin, Nabilah Khan, Daniel A Pollyea, Jason R Myers, John M Ashton, Michael W Becker, Vasilis Vasiliou, Keith R Humphries, Craig T Jordan, Clayton A Smith
Aldehyde dehydrogenase 1A1 (ALDH1A1) activity is high in hematopoietic stem cells and functions in part to protect stem cells from reactive aldehydes and other toxic compounds. In contrast, we found that ~25% of all acute myeloid leukemias expressed low or undetectable levels of ALDH1A1 and that this ALDH1A1- subset of leukemias correlates with good prognosis cytogenetics. ALDH1A1- cell lines as well as primary leukemia cells were found to be sensitive to treatment with compounds that directly and indirectly generate toxic ALDH substrates including 4-hydroxynonenal and the clinically relevant compounds arsenic trioxide and 4-hydroperoxycyclophosphamide...
March 9, 2017: Haematologica
https://www.readbyqxmd.com/read/28278714/cucurbitacin-b-synergistically-enhances-the-apoptosis-inducing-effect-of-arsenic-trioxide-by-inhibiting-stat3-phosphorylation-in-lymphoma-ramos-cells
#14
Xiuli Ding, Jiadong Chi, Xue Yang, Jian Hao, Chang Liu, Cuihong Zhu, Xiaodong Wang, Xiaohui Liu, Yangyang Niu, Wei Ji, Dan Chen, Xiongzhi Wu
Arsenic trioxide (ATO) is a classic apoptosis-inducing agent used to treat acute promyelocytic leukemia. However, the therapeutic effect of ATO is limited in lymphoma, which resists apoptosis possibly due to inappropriate activation of STAT3. Therefore, combination of ATO and STAT3 inhibitor may be a potential strategy to treat lymphoma. Dramatically, Cucurbitacin B (CuB), an effective component of the dichloromethane extraction from Trichosanthes kirilowii Maxim, synergistically eliminated the apoptosis resistance of Burkitt's lymphoma Ramos cells to ATO by inhibiting the phosphorylation of STAT3, followed in turn by downregulation of Bcl-2 and upregulation of Bax...
February 20, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28276286/arsenic-trioxide-and-all-trans-retinoic-acid-selectively-exert-synergistic-cytotoxicity-against-flt3-itd-aml-cells-via-co-inhibition-of-flt3-signaling-pathways
#15
Li-Na Wang, Yan-Lai Tang, Yin-Chuan Zhang, Zu-Han Zhang, Xiao-Jian Liu, Zhi-Yong Ke, Yu Li, Hui-Zhen Tan, Li-Bin Huang, Xue-Qun Luo
FLT3-ITD mutations occur in approximately 30% of acute myeloid leukemia (AML) and are associated with a poor outcome. Currently available FLT3 inhibitors have in vitro but limited clinical activity in FLT3-ITD AML. Reports have shown that an arsenic trioxide (ATO)/all-trans-retinoic acid (ATRA) combination improves prognosis in acute promyelocytic leukemia, especially with FLT3-ITD, and ATO or ATRA alone enhances apoptosis in FLT3-ITD AML cells treated with FLT3 inhibitors, providing a rationale to investigate the role of ATO/ATRA in FLT3-ITD AML...
March 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28265077/arsenic-trioxide-targets-mthfd1-and-sumo-dependent-nuclear-de-novo-thymidylate-biosynthesis
#16
Elena Kamynina, Erica R Lachenauer, Aislyn C DiRisio, Rebecca P Liebenthal, Martha S Field, Patrick J Stover
Arsenic exposure increases risk for cancers and is teratogenic in animal models. Here we demonstrate that small ubiquitin-like modifier (SUMO)- and folate-dependent nuclear de novo thymidylate (dTMP) biosynthesis is a sensitive target of arsenic trioxide (As2O3), leading to uracil misincorporation into DNA and genome instability. Methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) and serine hydroxymethyltransferase (SHMT) generate 5,10-methylenetetrahydrofolate for de novo dTMP biosynthesis and translocate to the nucleus during S-phase, where they form a multienzyme complex with thymidylate synthase (TYMS) and dihydrofolate reductase (DHFR), as well as the components of the DNA replication machinery...
March 21, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28262482/cytotoxicity-and-genotoxicity-effects-of-arsenic-trioxide-on-sq20b-human-laryngeal-carcinoma-cells
#17
Fatma Trabelsi, Rim Khlifi, Didier Goux, Marilyne Guillamin, Amel Hamza-Chaffai, François Sichel
This study investigates the cytotoxicity and the genotoxicity induced by arsenic trioxide As2O3in human laryngeal SQ20B carcinoma cell line. SQ20B cells were exposed to graded concentrations of arsenic trioxide (2 and 5μM) for 48h. Comet assay and γ-H2AX foci formation were used for measuring DNA damages, flow cytometry was used to identify cell cycle alterations and apoptosis, while cell morphology was visualized using transmission electron microscopy. The results show a dose-dependent induction of DNA damages and double strand breaks, alterations in cell cycle and morphologic alterations of cells...
March 2, 2017: Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Für Toxikologische Pathologie
https://www.readbyqxmd.com/read/28261759/dihydroartemisinin-sensitizes-human-lung-adenocarcinoma-a549-cells-to-arsenic-trioxide-via-apoptosis
#18
Hongyu Chen, Shiyan Gu, Huangmei Dai, Xinyang Li, Zunzhen Zhang
Recent studies have shown that arsenic trioxide (ATO) is an effective anti-cancer drug for treatment of acute promyelocytic leukemia and other types of human cancer. However, we have found that lung cancer cells constantly develop a high level of resistance to ATO. In this study, we have explored a possibility of combination of dihydroartemisinin (DHA) and ATO treatments to reduce ATO resistance of lung cancer cells. We determined the combinatory effects of DHA and ATO on cytotoxicity of human lung adenocarcinoma (A549) cells...
March 6, 2017: Biological Trace Element Research
https://www.readbyqxmd.com/read/28254430/anti-tumor-activity-of-pi3k-%C3%AE-inhibitor-in-hematologic-malignant-cells-shedding-new-light-on-resistance-to-idelalisib
#19
Davood Bashash, Ava Safaroghli-Azar, Maryam Dadashi, Majid Safa, Majid Momeny, Seyed H Ghaffari
Genetic and laboratory experiments have brought remarkable advances in management of human malignancies, which not only revolutionized the understanding of the disease, but also led to development of novel and effective targeted therapies against specific deregulated pathways. This study aimed to investigate anti-cancer effects of Idelalisib, a potent PI3K-δ inhibitor, in a panel of hematological cell lines. The resulting data showed that Idelalisib decreased cell survival in all the tested cell lines; however, as compared to NB4, viability of other cell lines, irrespective of their molecular characteristics or even the compensatory activation of MEK/ERK pathway, was inhibited at higher concentrations...
February 22, 2017: International Journal of Biochemistry & Cell Biology
https://www.readbyqxmd.com/read/28245381/-effect-of-arsenic-trioxide-on-k562-cell-proliferation-and-its-mechanism
#20
Yuan Wang, Jie Yang, Jie Li, Rui-Cang Wang, Jun Yuan, Yan Li, Su-Yun Wang, Chao Wang, Hong-Ling Hao
OBJECTIVE: To investigate the molecular mechanism of arsenic trioxide(ATO) inhibiting K562 cell proliferation, and explore the new targets for treating chronic myeloid leukemia(CML). METHODS: human CML cell line K562 cells were cultured in vitro, and were treated with different concentrations of ATO; MTT was used to detect the cell proliferation; flow cytometry(FCM) was used to determine cell apoptosis, cell cycle and the expression of CD44; Transcriptional levels of β-catenin and cyclin D1 were assayed by RT-PCR...
February 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
keyword
keyword
62382
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"